Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis

Nature Reviews Neurology

Volumn 10, Issue 4, 2014, Pages 225-238

  Friese, Manuel A ^a   Schattling, Benjamin ^a   Fugger, Lars ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; AMILORIDE; BIOLOGICAL MARKER; CALCIUM CHANNEL; CALPASTATIN; CANNABINOID DERIVATIVE; CD200 RECEPTOR; CHEMOKINE; CYTOKINE; ERYTHROPOIETIN; GLUTAMIC ACID; HEME OXYGENASE 1; HLA DRB1 ANTIGEN; ION CHANNEL; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NATALIZUMAB; NEUROFILAMENT PROTEIN; NEUROPROTECTIVE AGENT; NEUROTROPHIN; POTASSIUM CHANNEL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SIRTUIN 1; SODIUM CHANNEL; TRANSCRIPTION FACTOR NRF2; TRANSIENT RECEPTOR POTENTIAL CHANNEL;

APOPTOSIS; AXONAL INJURY; CHANNELOPATHY; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG TARGETING; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NEUROAXONAL DYSTROPHY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WALLERIAN DEGENERATION;

ANIMALS; APOPTOSIS; AXONS; BIOLOGICAL MARKERS; HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; SIGNAL TRANSDUCTION; WALLERIAN DEGENERATION;

EID: 84898017077     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.37     Document Type: Review

References (165)

1. Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502-1517 (2008
2. Weiner, H. L. A shift from adaptive to innate immunity: A potential mechanism of disease progression in multiple sclerosis. J. Neurol. 255 (Suppl. 1), 3-11 (2008
3. Funfschilling, U. et al. Glycolytic oligodendrocytes maintain myelin and long-Term axonal integrity. Nature 485, 517-521 (2012
4. Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443-448 (2012
5. Frischer, J. M. et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175-1189 (2009
6. Kornek, B. et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157, 267-276 (2000
7. Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712 (2005
8. DeLuca, G. C., Ebers, G. C. & Esiri, M. M. Axonal loss in multiple sclerosis: A pathological survey of the corticospinal and sensory tracts. Brain 127, 1009-1018 (2004
9. Bitsch, A., Schuchardt, J., Bunkowski, S., Kuhlmann, T. & Bruck, W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123, 1174-1183 (2000
10. DeLuca, G. C., Williams, K., Evangelou, N., Ebers, G. C. & Esiri, M. M. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129, 1507-1516 (2006
11. Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A. & Ebers, G. C. Onset of secondary progressive phase and long-Term evolution of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 85, 67-75 (2014
12. Confavreux, C., Vukusic, S., Moreau, T. & Adeleine, P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343, 1430-1438 (2000
13. Scalfari, A. et al. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-Term disability. Brain 133, 1914-1929 (2010
14. Scalfari, A. et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol. 70, 214-222 (2013
15. Kappos, L. et al. Long-Term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5 year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 8, 987-997 (2009
16. Shirani, A. et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308, 247-256 (2012
17. Haghikia, A., Hohlfeld, R., Gold, R. & Fugger, L. Therapies for multiple sclerosis: Translational achievements and outstanding needs. Trends Mol. Med. 19, 309-319 (2013
18. Barkhof, F., Calabresi, P. A., Miller, D. H. & Reingold, S. C. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat. Rev. Neurol. 5, 256-266 (2009
19. Chard, D. T. et al. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 125, 327-337 (2002
20. Miller, D. H., Barkhof, F., Frank, J. A., Parker, G. J. & Thompson, A. J. Measurement of atrophy in multiple sclerosis: Pathological basis, methodological aspects and clinical relevance. Brain 125, 1676-1695 (2002
21. Petzold, A. et al. Optical coherence tomography in multiple sclerosis: A systematic review and meta-Analysis. Lancet Neurol. 9, 921-932 (2010
22. Kuhle, J. et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 76, 1206-1213 (2011
23. Gunnarsson, M. et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann. Neurol. 69, 83-89 (2011
24. Popescu, B. F. & Lucchinetti, C. F. Pathology of demyelinating diseases. Annu. Rev. Pathol. 7, 185-217 (2012
25. Bjartmar, C., Kidd, G., Mörk, S., Rudick, R. & Trapp, B. D. Neurological disability correlates with spinal cord axonal loss and reduced N acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48, 893-901 (2000
26. Dziedzic, T. et al. Wallerian Degeneration: A major component of early axonal pathology in multiple sclerosis. Brain Pathol. 20, 976-985 (2010
27. Peterson, J. W., Bö, L., Mörk, S., Chang, A. & Trapp, B. D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389-400 (2001
28. Vercellino, M. et al. Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol. 64, 1101-1107 (2005
29. Lucchinetti, C. F. et al. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188-2197 (2011
30. Kutzelnigg, A. et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 17, 38-44 (2007
31. Choi, S. R. et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 135, 2925-2937 (2012
32. Howell, O. W. et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134, 2755-2771 (2011
33. DeLuca, G. C. et al. Casting light on multiple sclerosis heterogeneity: The role of HLA-DRB1 on spinal cord pathology. Brain 136, 1025-1034 (2013
34. The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357, 851-862 (2007
35. Baranzini, S. E. et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum. Mol. Genet. 18, 767-778 (2009
36. Brynedal, B. et al. MGAT5 alters the severity of multiple sclerosis. J. Neuroimmunol. 220, 120-124 (2010
37. International Multiple Sclerosis Genetics Consortium. Genome-wide association study of severity in multiple sclerosis. Genes Immun. 12, 615-625 (2011
38. Baranzini, S. E. et al. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. Brain 133, 2603-2611 (2010
39. Friese, M. A. et al. The value of animal models for drug development in multiple sclerosis. Brain 129, 1940-1952 (2006
40. Haider, L. et al. Oxidative damage in multiple sclerosis lesions. Brain 134, 1914-1924 (2011
41. Zeis, T. et al. Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol. 19, 459-466 (2009
42. Nikic, I. et al. A reversible form of axon Damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 17, 495-499 (2011
43. Fischer, M. T. et al. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 136, 1799-1815 (2013
44. Gray, E., Thomas, T. L., Betmouni, S., Scolding, N. & Love, S. Elevated activity and microglial expression of myeloperoxidase in Demyelinated cerebral cortex in multiple sclerosis. Brain Pathol. 18, 86-95 (2008
45. Fischer, M. T. et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135, 886-899 (2012
46. Li, S., Vana, A. C., Ribeiro, R. & Zhang, Y. Distinct role of nitric oxide and peroxynitrite in mediating oligodendrocyte toxicity in culture and in experimental autoimmune encephalomyelitis. Neuroscience 184, 107-119 (2011
47. Smith, K. J., Kapoor, R., Hall, S. M. & Davies, M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 49, 470-476 (2001
48. Hametner, S. et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann. Neurol. 74, 846-861 (2013
49. Rathore, K. I. et al. Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage. J. Neurosci. 28, 12736-12747 (2008
50. Craelius, W., Migdal, M. W., Luessenhop, C. P., Sugar, A. & Mihalakis, I. Iron Deposits surrounding multiple sclerosis plaques. Arch. Pathol. Lab. Med. 106, 397-399 (1982
51. Bagnato, F. et al. Tracking iron in multiple sclerosis: A combined imaging and histopathological study at 7 Tesla. Brain 134, 3602-3615 (2011
52. Lopes, K. O., Sparks, D. L. & Streit, W. J. Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity. Glia 56, 1048-1060 (2008
53. Lassmann, H., van Horssen, J. & Mahad, D. Progressive multiple sclerosis: Pathology and pathogenesis. Nat. Rev. Neurol. 8, 647-656 (2012
54. Nathoo, N. et al. Susceptibility-weighted imaging in the experimental autoimmune encephalomyelitis model of multiple sclerosis indicates elevated deoxyhemoglobin, iron Deposition and demyelination. Mult. Scler. 19, 721-731 (2013
55. Kensler, T. W., Wakabayashi, N. & Biswal, S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116 (2007
56. van Horssen, J. et al. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic. Biol. Med. 45, 1729-1737 (2008
57. Chora, A. A. et al. Heme oxygenase 1 and carbon monoxide suppress autoimmune neuroinflammation. J. Clin. Invest. 117, 438-447 (2007
58. Pennisi, G. et al. Redox regulation of cellular stress response in multiple sclerosis. Biochem. Pharmacol. 82, 1490-1499 (2011
59. Johnson, D. A., Amirahmadi, S., Ward, C., Fabry, Z. & Johnson, J. A. The absence of the pro-Antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol. Sci. 114, 237-246 (2010
60. Linker, R. A. et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678-692 (2011
61. Ghoreschi, K. et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 208, 2291-2303 (2011
62. Schilling, S., Goelz, S., Linker, R., Luehder, F. & Gold, R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 145, 101-107 (2006
63. Lin, M. T. & Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795 (2006
64. Trapp, B. D. & Stys, P. K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 8, 280-291 (2009
65. Wallace, D. C., Fan, W. & Procaccio, V. Mitochondrial energetics and therapeutics. Annu. Rev. Pathol. 5, 297-348 (2010
66. Trifunovic, A. et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429, 417-423 (2004
67. Echaniz-Laguna, A. et al. POLG1 variations presenting as multiple sclerosis. Arch. Neurol. 67, 1140-1143 (2010
68. Kim, J. Y. et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat. Neurosci. 13, 180-189 (2010
69. Shindler, K. S. et al. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J. Neuroophthalmol. 30, 328-339 (2010
70. Park, S. J. et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421-433 (2012
71. Forte, M. et al. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl Acad. Sci. USA 104, 7558-7563 (2007
72. Friese, M. A. et al. Acid-sensing ion channel 1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat. Med. 13, 1483-1489 (2007
73. Aboul-Enein, F. et al. Preferential loss of myelin-Associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain Diseases. J. Neuropathol. Exp. Neurol. 62, 25-33 (2003
74. Graumann, U., Reynolds, R., Steck, A. J. & Schaeren-Wiemers, N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 13, 554-573 (2003
75. Howarth, C., Gleeson, P. & Attwell, D. Updated energy budgets for neural computation in the neocortex and cerebellum. J. Cereb. Blood Flow Metab. 32, 1222-1232 (2012
76. Paling, D. et al. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. Brain 136, 2305-2317 (2013
77. Young, E. A. et al. Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann. Neurol. 63, 428-435 (2008
78. Craner, M. J. et al. Molecular changes in neurons in multiple sclerosis: Altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc. Natl Acad. Sci. USA 101, 8168-8173 (2004
79. Alle, H., Roth, A. & Geiger, J. R. Energy-efficient action potentials in hippocampal mossy fibers. Science 325, 1405-1408 (2009
80. Carter, B. C. & Bean, B. P. Sodium entry during action potentials of mammalian neurons: Incomplete inactivation and reduced metabolic efficiency in fast-spiking neurons. Neuron 64, 898-909 (2009
81. Hodgkin, A. The optimum density of sodium channels in an unmyelinated nerve. Philos. Trans. R. Soc. Lond. B Biol. Sci. 270, 297-300 (1975
82. Craner, M. J., Hains, B. C., Lo, A. C., Black, J. A. & Waxman, S. G. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 127, 294-303 (2004
83. O'Malley, H. A., Shreiner, A. B., Chen, G. H., Huffnagle, G. B. & Isom, L. L. Loss of Na+ channel β2 subunits is neuroprotective in a mouse model of multiple sclerosis. Mol. Cell. Neurosci. 40, 143-155 (2009
84. Bechtold, D. A., Kapoor, R. & Smith, K. J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol. 55, 607-616 (2004
85. Morsali, D. et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain 136, 1067-1082 (2013
86. Black, J. A., Liu, S., Carrithers, M., Carrithers, L. M. & Waxman, S. G. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann. Neurol. 62, 21-33 (2007
87. Lo, A. C., Saab, C. Y., Black, J. A. & Waxman, S. G. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J. Neurophysiol. 90, 3566-3571 (2003
88. Bechtold, D. A. et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J. Neurol. 253, 1542-1551 (2006
89. Craner, M. J. et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49, 220-229 (2005
90. Kapoor, R. et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 9, 681-688 (2010
91. Shields, S. D. et al. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis. Ann. Neurol. 71, 186-194 (2012
92. Moran, M. M., McAlexander, M. A., Biro, T. & Szallasi, A. Transient receptor potential channels as therapeutic targets. Nat. Rev. Drug Discov. 10, 601-620 (2011
93. Guinamard, R., Demion, M. & Launay, P. Physiological roles of the TRPM4 channel extracted from background currents. Physiology (Bethesda) 25, 155-164 (2010
94. Schattling, B. et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat. Med. 18, 1805-1811 (2012
95. Dunn, J. & Blight, A. Dalfampridine: A brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr. Med. Res. Opin. 27, 1415-1423 (2011
96. Jukkola, P. I., Lovett-Racke, A. E., Zamvil, S. S. & Gu, C. K+ channel alterations in the progression of experimental autoimmune encephalomyelitis. Neurobiol. Dis. 47, 280-293 (2012
97. Beraud, E. et al. Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy. Ann. Neurol. 60, 586-596 (2006
98. Mathie, A. & Veale, E. L. Therapeutic potential of neuronal two-pore domain potassium-channel modulators. Curr. Opin. Investig. Drugs 8, 555-562 (2007
99. Bittner, S. et al. TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain 132, 2501-2516 (2009
100. Bittner, S. et al. The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis. Exp. Neurol. 238, 149-155 (2012
101. Brand-Schieber, E. & Werner, P. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis. Exp. Neurol. 189, 5-9 (2004
102. Waxman, S. G. & Ritchie, J. M. Molecular dissection of the myelinated axon. Ann. Neurol. 33, 121-136 (1993
103. Kornek, B. et al. Distribution of a calcium channel subunit in Dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 124, 1114-1124 (2001
104. Gadjanski, I. et al. Role of N type voltage-dependent calcium channels in autoimmune optic neuritis. Ann. Neurol. 66, 81-93 (2009
105. Stirling, D. P. & Stys, P. K. Mechanisms of axonal injury: Internodal nanocomplexes and calcium deregulation. Trends Mol. Med. 16, 160-170 (2010
106. Hardingham, G. E. & Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682-696 (2010
107. Mahad, D. J. et al. Mitochondrial changes within axons in multiple sclerosis. Brain 132, 1161-1174 (2009
108. Grasselli, G. et al. Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis. Br. J. Pharmacol. 168, 502-517 (2013
109. Sarchielli, P., Greco, L., Floridi, A. & Gallai, V. Excitatory amino acids and multiple sclerosis: Evidence from cerebrospinal fluid. Arch. Neurol. 60, 1082-1088 (2003
110. Piani, D., Frei, K., Do, K. Q., Cuenod, M. & Fontana, A. Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci. Lett. 133, 159-162 (1991
111. Newcombe, J. et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol. 18, 52-61 (2008
112. Vercellino, M. et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: Correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J. Neuropathol. Exp. Neurol. 66, 732-739 (2007
113. Hardin-Pouzet, H. et al. Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis. Glia 20, 79-85 (1997
114. Ohgoh, M. et al. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 125, 170-178 (2002
115. Pitt, D., Werner, P. & Raine, C. S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6, 67-70 (2000
116. Smith, T., Groom, A., Zhu, B. & Turski, L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6, 62-66 (2000
117. Kanwar, J. R., Kanwar, R. K. & Krissansen, G. W. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 127, 1313-1331 (2004
118. Paul, C. & Bolton, C. Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N methyl d-Aspartate receptor antagonist memantine. J. Pharmacol. Exp. Ther. 302, 50-57 (2002
119. Wallstrom, E. et al. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J. Neurol. Sci. 137, 89-96 (1996
120. Centonze, D. et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 29, 3442-3452 (2009
121. Basso, A. S. et al. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest. 118, 1532-1543 (2008
122. Wemmie, J. A., Taugher, R. J. & Kreple, C. J. Acid-sensing ion channels in pain and disease. Nat. Rev. Neurosci. 14, 461-471 (2013
123. Yermolaieva, O., Leonard, A. S., Schnizler, M. K., Abboud, F. M. & Welsh, M. J. Extracellular acidosis increases neuronal cell calcium by activating acid-sensing ion channel 1a. Proc. Natl Acad. Sci. USA 101, 6752-6757 (2004
124. Vergo, S. et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. Brain 134, 571-584 (2011
125. Arun, T. et al. Targeting ASIC1 in primary progressive multiple sclerosis: Evidence of neuroprotection with amiloride. Brain 136, 106-115 (2013
126. Hassen, G. W., Feliberti, J., Kesner, L., Stracher, A. & Mokhtarian, F. Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. Brain Res. 1236, 206-215 (2008
127. Shields, D. C., Tyor, W. R., Deibler, G. E., Hogan, E. L. & Banik, N. L. Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc. Natl Acad. Sci. USA 95, 5768-5772 (1998
128. Guyton, M. K. et al. Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. J. Neurosci. Res. 81, 53-61 (2005
129. Offen, D. et al. Mice overexpressing Bcl 2 in their neurons are resistant to myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE). J. Mol. Neurosci. 15, 167-176 (2000
130. Aktas, O. et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46, 421-432 (2005
131. Chitnis, T. et al. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am. J. Pathol. 170, 1695-1712 (2007
132. Saxena, S. & Caroni, P. Selective neuronal vulnerability in neurodegenerative diseases: From stressor thresholds to degeneration. Neuron 71, 35-48 (2011
133. Kemp, J. A. & McKernan, R. M. NMDA receptor pathways as drug targets. Nat. Neurosci. 5 (Suppl.), 1039-1042 (2002
134. Stranahan, A. M. & Mattson, M. P. Recruiting adaptive cellular stress responses for successful brain ageing. Nat. Rev. Neurosci. 13, 209-216 (2012
135. Prakash, R. S., Snook, E. M., Motl, R. W. & Kramer, A. F. Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis. Brain Res. 1341, 41-51 (2010
136. Briken, S. et al. Effects of exercise on fitness and cognition in progressive MS: A randomized, controlled pilot trial. Mult. Scler. http://dx.doi.org/10.1177/1352458513507358
137. Rossi, S. et al. Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiol. Dis. 36, 51-59 (2009
138. Safdar, A. et al. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc. Natl Acad. Sci. USA 108, 4135-4140 (2011
139. Maresz, K. et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492-497 (2007
140. Kaneko, S. et al. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J. Neurosci. 26, 9794-9804 (2006
141. Dutta, R. et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59, 478-489 (2006
142. Campbell, G. R. et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann. Neurol. 69, 481-492 (2011
143. Mahad, D., Ziabreva, I., Lassmann, H. & Turnbull, D. Mitochondrial defects in acute multiple sclerosis lesions. Brain 131, 1722-1735 (2008
144. Zambonin, J. L. et al. Increased mitochondrial content in remyelinated axons: Implications for multiple sclerosis. Brain 134, 1901-1913 (2011
145. Linker, R. A. et al. CNTF is a major protective factor in Demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 8, 620-624 (2002
146. Linker, R. A. et al. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: Therapeutic implications in a model of multiple sclerosis. Brain 133, 2248-2263 (2010
147. Lu, B., Nagappan, G., Guan, X., Nathan, P. J. & Wren, P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat. Rev. Neurosci. 14, 401-416 (2013
148. Petryshen, T. L. et al. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry 15, 810-815 (2010
149. Zivadinov, R. et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum. Mol. Genet. 16, 2659-2668 (2007
150. Ramasamy, D. P. et al. Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. Pathophysiology 18, 53-60 (2011
151. Nagahara, A. H. & Tuszynski, M. H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 10, 209-219 (2011
152. Stadelmann, C. et al. BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells?. Brain 125, 75-85 (2002
153. Kerschensteiner, M. et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of inflammation?. J. Exp. Med. 189, 865-870 (1999
154. Lee, D. H. et al. Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol. 123, 247-258 (2012
155. Colombo, E. et al. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J. Exp. Med. 209, 521-535 (2012
156. Jones, J. L. et al. Improvement in Disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133, 2232-2247 (2010
157. Thone, J. et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol. 180, 267-274 (2012
158. Marsicano, G. et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302, 84-88 (2003
159. Pryce, G. et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-2202 (2003
160. Rossi, S. et al. Cannabinoid CB1 receptors regulate neuronal TNF a effects in experimental autoimmune encephalomyelitis. Brain Behav. Immun. 25, 1242-1248 (2011
161. Croxford, J. L. et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J. Neuroimmunol. 193, 120-129 (2008
162. Zajicek, J. et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): A randomised, placebo-controlled trial. Lancet Neurol. 12, 857-865 (2013
163. Broxmeyer, H. E. Erythropoietin: Multiple targets, actions, and modifying influences for biological and clinical consideration. J. Exp. Med. 210, 205-208 (2013
164. Li, W. et al. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann. Neurol. 56, 767-777 (2004
165. Suhs, K. W. et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann. Neurol. 72, 199-210 (2012.